Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.
Moree
Wilna J
WJ
Deltagen Research Laboratories, 4570 Executive Drive, Suite 400, San Diego, CA 92121, USA. wmoree@neurocrine.com
Kataoka
Ken-ichiro
K
Ramirez-Weinhouse
Michele M
MM
Shiota
Tatsuki
T
Imai
Minoru
M
Sudo
Masaki
M
Tsutsumi
Takaharu
T
Endo
Noriaki
N
Muroga
Yumiko
Y
Hada
Takahiko
T
Tanaka
Hiroko
H
Morita
Takuya
T
Greene
Jonathan
J
Barnum
Doug
D
Saunders
John
J
Kato
Yoshinori
Y
Myers
Peter L
PL
Tarby
Christine M
CM
D002460:Cell Line; D018932:Chemokine CCL2 / Q000378:metabolism; D002633:Chemotaxis / Q000187:drug effects; D020650:Combinatorial Chemistry Techniques; D003959:Diamines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D010880:Piperidines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D011759:Pyrrolidines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D011869:Radioligand Assay; D054390:Receptors, CCR2; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
C515334:CCR2 protein, human; D018932:Chemokine CCL2; D003959:Diamines; D010880:Piperidines; D011759:Pyrrolidines; D054390:Receptors, CCR2; D019707:Receptors, Chemokine